
Active Pharmaceutical Ingredient Market By Manufacturing Process (Captive Manufacturing, Contract Manufacturing), By API Type (Synthetic API, Biological API), By Therapeutic Area (Diabetes, Oncology, Others) and Region - Global Forecast 2028
-
2766
-
April 2018
-
145
-
PDF
-
-
Request for Sample
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
The Active Pharmaceutical Ingredient Market report offers in-depth insights, revenue details, and other vital information regarding the global interior wall putty powder market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2028. The Active Pharmaceutical Ingredient Market report also offers insightful and detailed information regarding the various key players operating in the global interior wall putty powder market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global active pharmaceutical ingredient market is segmented on the basis of the manufacturing process, API type, drug type, therapeutic area, and region.
Global Active Pharmaceutical Ingredients Market: Overview
The Active Pharmaceutical Ingredient Market was valued at $183.4 billion in 2021 & is projected to reach $279.4 billion by 2027. It is expected to grow at a 7.8% CAGR between 2021 and 2027.
Active Pharmaceutical Ingredients (API) is commonly referred as ‘Drug substance” or ‘Bulk pharmaceutical chemical’. Active ingredient is the substance which is biologically active in pharmaceutical drug. Active Pharmaceutical Ingredients (API) of good quality are core to the manufacturing of effective and safe essential drugs.
Initially only limited number of large manufacturers of finished pharmaceutical products have their own API manufacturing plants. The majority of manufacturers used to buy all APIs from the open market. Some drug contains more than one active pharmaceutical ingredients.
All drug contains two main components, active pharmaceutical ingredient(API) which is the main component that shows the therapeutic effect, and excipients which helps in the delivery of medication. Excipients are chemically inactive substances such as mineral oil, that act as vehicles for conveying active ingredients to the target site.
Active Pharmaceutical Ingredients(API) play important role in diseases prevention and treatment. For any disease, treatment is chosen on the bases of the active ingredient used in it.
Global Active Pharmaceutical Ingredients Market: Dynamics
Primary factors driving growth of the global active pharmaceutical ingredients market is increasing the incidence of chronic diseases and illnesses.
Moreover, factors such as growing trend related to new high-tech therapeutics, the development of innovative and novel delivery systems, and technological advancements for manufacturing of API are some of the factors are expected to boost active pharmaceutical ingredients market globally.
In addition, import-export policies across countries and Adoption of herbal and homeopathy are the major factors hinder the demand of API globally.
Global Active Pharmaceutical Ingredients Market Analysis, by Manufacturing Process:
On the basis of the manufacturing process, the market is segmented into captive manufacturing and contract manufacturing. Among the manufacturing process segments in 2019, the captive manufacturing segment is estimated to account for highest revenue share in the global market.
Revenue from the contract manufacturing segment is projected to expand at CAGR of over 6.4%.
Global Active Pharmaceutical Ingredients Market Analysis, by API Type:
Based on API type, the global market is segmented into synthetic API and biological API. The synthetic API segment accounts for maximum share and is expected to continue to grow at the same rate over the forecast period. Among the API type segments in 2019, The biological API segment is expected to register a CAGR of over 6.8% between 2018 and 2028.
Global Active Pharmaceutical Ingredients Market Analysis, by Drug Type:
Based on drug type, the global market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment accounts for maximum share and is expected to continue to grow at the same rate over the forecast period. Revenue from the prescription drugs segment is projected to expand at highest CAGR of 6.3% over the forecast period
Global Active Pharmaceutical Ingredients Market Analysis, by Therapeutic Area:
Based on therapeutic area, the global market is segmented into communicable diseases, oncology, ophthalmology, cardiovascular diseases, diabetes, respiratory diseases, and other.
Among the therapeutic area segments in 2018, the oncology segment is estimated to account for highest revenue share in the global market. Revenue from the oncology segment is projected to expand at the highest CAGR of 6.9% over the forecast period.
Global Active Pharmaceutical Ingredients Market Analysis, by Region:
Based on region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market in North America accounted for dominant revenue share in the global active pharmaceutical ingredients market in 2019, and is projected to dominate the target market over the forecast period. Revenue from the market in the Asia Pacific is projected to register the highest CAGR of 6.6%.
Presence of major players, coupled with increasing R&D activities for the development of innovative products is expected to further support growth of the market in this region over the forecast period.
Increasing incidence of chronic diseases, a significant rise in the geriatric population in recent times, and increasing R&D activities regarding drugs specific to novel biomarkers in countries in the region are some other major factors driving the growth of the active pharmaceutical ingredients market in the Asia Pacific currently.
- According to WHO, 90% of new cancer cases diagnosed each year in the Western Pacific Region are in developing countries. In addition, Cancer kills an estimated 1.1 million people in the South-East Asia Region each year
- According to WHO, cardiovascular diseases are the largest killers — annually claiming 17.3 million lives globally (63% of all deaths) and 3.6 million lives in SEAR. Cardiovascular diseases are killing people at a relatively younger age in the Region; 27% of all deaths due to cardiovascular diseases in the Region occur before the age of 60 years compared to 16% in the rest of the world
- According to WHO, about 131 million people in the Western Pacific Region had diabetes in 2014. 75% of diabetes cases diagnosed each year in the Western Pacific Region are in developing countries. 1 million die every year in SEA Region from consequences of high blood sugar. If uncontrolled, the diabetes burden will double by 2030 in the Region
Market Segmentation of Global Active Pharmaceutical Ingredient Market:
Segmentation by Manufacturing Process:
- Captive Manufacturing
- Contract Manufacturing
Segmentation by API Type:
- Synthetic API
- Biological API
Segmentation by Drug Type:
- Prescription Drugs
- Over-The-Counter Drugs
Segmentation by Therapeutic Area:
- Communicable Diseases
- Oncology
- Opthalmology
- Cardiovascular Diseases
- Diabetes
- Respiratory Diseases
- Other
Segmentation by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
-
- Teva Pharmaceutical Industries Ltd.
- Merck & Co.
- Mylan N.V.
- Sanofi
- Ipca Laboratories Ltd.
- Aurobindo Pharma
- Cipla Limited
- Lupin Limited
- GlaxoSmithKline plc
- Novartis Pharmaceuticals Corporation
-
- 1 Chapter 1
- 1.1 Preface
- 1.2 Assumptions
- 1.3 Abbreviations
- 2 Chapter 2
- 2.1 Report Description
- 2.1.1 Market Definition and Scope
- 2.2 Executive Summary
- 2.2.1 Market Snapshot, By Manufacturing Process
- 2.2.2 Market Snapshot, By API Type
- 2.2.3 Market Snapshot, By Drug Type
- 2.2.4 Market Snapshot, By Therapeutic Area
- 2.2.5 Market Snapshot, By Region
- 2.2.6 Prudour Opportunity Map Analysis
- 2.1 Report Description
- 3 Chapter 3
- 3.0.1 Global Active Pharmaceutical Ingredients Market Dynamics
- 3.0.2 Drivers
- 3.0.3 Restraints
- 3.0.4 Opportunities
- 3.0.5 Trends
- 3.0.6 PEST Analysis
- 3.0.7 PORTER’S Five Forces Analysis
- 4 Chapter 4
- 4.0.1 Global Active Pharmaceutical Ingredients Market Analysis, by Manufacturing Process
- 4.0.2 Overview
- 4.0.3 Segment Trends
- 4.0.4 Market Value (US$ Mn) and Forecast, 2018–2028
- 4.1 Captive Manufacturing
- 4.1.1 Overview
- 4.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 4.2 Contract Manufacturing
- 4.2.1 Overview
- 4.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 5 Chapter 5
- 5.0.1 Global Active Pharmaceutical Ingredients Market Analysis, by API Type
- 5.0.2 Overview
- 5.0.3 Segment Trends
- 5.0.4 Market Value (US$ Mn) and Forecast, 2018–2028
- 5.1 Synthetic API
- 5.1.1 Overview
- 5.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 5.2 Biological API
- 5.2.1 Overview
- 5.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6 Chapter 6
- 6.0.1 Global Active Pharmaceutical Ingredients Market Analysis, by Drug Type
- 6.0.2 Overview
- 6.0.3 Segment Trends
- 6.0.4 Market Value (US$ Mn) and Forecast, 2018–2028
- 6.1 Prescription Drugs
- 6.1.1 Overview
- 6.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 6.2 OTC Drugs
- 6.2.1 Overview
- 6.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7 Chapter 7
- 7.0.1 Global Active Pharmaceutical Ingredients Market Analysis, by Therapeutic Area
- 7.0.2 Overview
- 7.0.3 Segment Trends
- 7.0.4 Market Value (US$ Mn) and Forecast, 2018–2028
- 7.1 Communicable Diseases
- 7.1.1 Overview
- 7.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.2 Oncology
- 7.2.1 Overview
- 7.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.3 Ophthalmology
- 7.3.1 Overview
- 7.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.4 Cardiovascular Diseases
- 7.4.1 Overview
- 7.4.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.5 Diabetes
- 7.5.1 Overview
- 7.5.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.6 Respiratory Diseases
- 7.6.1 Overview
- 7.6.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 7.7 Others
- 7.7.1 Overview
- 7.7.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 8 Chapter 8
- 8.0.1 Global Active Pharmaceutical Ingredients Market Analysis, by Region
- 8.0.2 Market Attractiveness Index
- 8.0.3 Overview
- 8.0.4 Regional Trends
- 8.0.5 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.1 Global Active Pharmaceutical Ingredients Market Analysis, by North America
- 8.1.1 Overview
- 8.1.2 Country Trends
- 8.1.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 8.1.4 US
- 8.1.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.1.5 Canada
- 8.1.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.2 Global Active Pharmaceutical Ingredients Market Analysis, by Europe
- 8.2.1 Overview
- 8.2.2 Country Trends
- 8.2.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 8.2.4 Germany
- 8.2.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.2.5 UK
- 8.2.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.2.6 France
- 8.2.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.2.7 Russia
- 8.2.7.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.2.8 Italy
- 8.2.8.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.2.9 Rest of Europe
- 8.2.9.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.3 Global Active Pharmaceutical Ingredients Market Analysis, by Asia Pacific
- 8.3.1 Overview
- 8.3.2 Country Trends
- 8.3.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 8.3.4 China
- 8.3.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.3.5 India
- 8.3.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.3.6 Japan
- 8.3.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.3.7 Australia
- 8.3.7.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.3.8 Rest of Asia Pacific
- 8.3.8.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.4 Global Active Pharmaceutical Ingredients Market Analysis, by Latin America
- 8.4.1 Overview
- 8.4.2 Country Trends
- 8.4.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 8.4.4 Brazil
- 8.4.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.4.5 Mexico
- 8.4.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.4.6 Rest of Latin America
- 8.4.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.4.6.2 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.5 Global Active Pharmaceutical Ingredients Market Analysis, by Middle East & Africa
- 8.5.1 Overview
- 8.5.2 Country Trends
- 8.5.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2018–2028
- 8.5.4 GCC
- 8.5.4.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.5.5 Israel
- 8.5.5.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.5.6 South Africa
- 8.5.6.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 8.5.7 Rest of Middle East & Africa
- 8.5.7.1 Market Value (US$ Mn) and Forecast, 2018–2028
- 9 Chapter 9
- 9.0.1 Company Profiles
- 9.1 Teva Pharmaceutical Industries Ltd.
- 9.1.1 Company Overview
- 9.1.2 Product Portfolio
- 9.1.3 Financial Overview
- 9.1.4 Recent Developments
- 9.1.5 SWOT Analysis
- 9.2 Merck & Co.
- 9.2.1 Company Overview
- 9.2.2 Product Portfolio
- 9.2.3 Financial Overview
- 9.2.4 Recent Developments
- 9.2.5 SWOT Analysis
- 9.3 Mylan N.V.
- 9.3.1 Company Overview
- 9.3.2 Product Portfolio
- 9.3.3 Financial Overview
- 9.3.4 Recent Developments
- 9.3.5 SWOT Analysis
- 9.4 Sanofi
- 9.4.1 Company Overview
- 9.4.2 Product Portfolio
- 9.4.3 Financial Overview
- 9.4.4 Recent Developments
- 9.4.5 SWOT Analysis
- 9.5 Ipca Laboratories Ltd.
- 9.5.1 Company Overview
- 9.5.2 Product Portfolio
- 9.5.3 Financial Overview
- 9.5.4 Recent Developments
- 9.5.5 SWOT Analysis
- 9.6 Aurobindo Pharma
- 9.6.1 Company Overview
- 9.6.2 Product Portfolio
- 9.6.3 Financial Overview
- 9.6.4 Recent Developments
- 9.6.5 SWOT Analysis
- 9.7 Cipla Limited
- 9.7.1 Company Overview
- 9.7.2 Product Portfolio
- 9.7.3 Financial Overview
- 9.7.4 Recent Developments
- 9.7.5 SWOT Analysis
- 9.8 Lupin Limited
- 9.8.1 Company Overview
- 9.8.2 Product Portfolio
- 9.8.3 Financial Overview
- 9.8.4 Recent Developments
- 9.8.5 SWOT Analysis
- 9.9 GlaxoSmithKline plc
- 9.9.1 Company Overview
- 9.9.2 Product Portfolio
- 9.9.3 Financial Overview
- 9.9.4 Recent Developments
- 9.9.5 SWOT Analysis
- 9.1 Novartis Pharmaceuticals Corporation
- 9.10.1 Company Overview
- 9.10.2 Product Portfolio
- 9.10.3 Financial Overview
- 9.10.4 Recent Developments
- 9.10.5 SWOT Analysis
- 10 Chapter 10
- 10.0.1 Research Methodology
- 10.0.2 About Us
- 10.0.3 Disclaimer
- 1 Chapter 1
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!